Keeping Pace with the Latest Updates in IgAN Disease and Treatments (Module 2)
Released On
Febuary 4, 2026
Expires On
Febuary 4, 2027
Media Type
Internet
Completion Time
30 minutes
Specialty
Nephrology
Topics
IgAN
This program has been funded by an unrestricted educational grant from Calliditas.
Credit Available
- Physicians - maximum of 0.5 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of US-based academic and community nephrologists and other healthcare professionals involved in the management of IgA nephropathy (IgAN).
Program Overview
Join leading nephrology experts for a series of 15-minute talking head videos that delve into the significant clinical burden of IgA nephropathy (IgAN), the underlying immune mechanisms driving disease progression, and the latest therapeutic advances transforming its management. The series emphasizes the importance of timely identification and diagnosis to ensure patients are connected to appropriate care and highlights how emerging therapies, targeting various stages of the IgAN pathogenic pathway, are reshaping the treatment landscape.
Episode 3: Changing the course: Guideline updates in IgAN management
Jonathan Barratt & Kirk Campbell
Duration of episode 3A: 17:45 minutes
Duration of episode 3B: 18:38 minutes
Learning Objectives
Upon completion of this educational activity, participants should be better able to:
- Interpret the updated KDIGO guideline recommendations for the diagnosis and management of igAN
- Apply guideline-informed strategies to identify patients with IgAN who require treatment and select appropriate therapeutic approaches
Gauge
GAUGE is Nexus Healthcare Education’s (Nexus HE’s) advanced outcome measurement tool, uniquely designed to evaluate the real-world impact of learning on clinical practice and patient care. In completing each of GAUGE's outcome assessments, you actively contribute to advancing the quality of healthcare education.
How Gauge Works
- Participation tracking: GAUGE monitors your engagement, including time spent on modules, and completion rates, providing insights into commitment to learning.
- Satisfaction feedback: After listening to the episodes, you will be asked to complete a satisfaction survey. This helps us capture your perceptions, identify strengths, and pinpoint areas for improvement to continually optimize our programs.
- Knowledge assessment: Pre- and post-module quizzes are used to measure knowledge gains. These assessments are designed to ensure the program effectively addresses your practice needs and supports your growth in clinical competence.
- Competency evaluation: Using practical, case-based scenarios via the Clinical Challenge Quiz, GAUGE evaluates readiness to apply new knowledge in real-world settings. Follow-up assessments at 1, 3, and 6 months post completion help track confidence and ability to implement changes over time.
- Performance and patient care impact: Through self-reported Patient Care Logs, GAUGE tracks the direct consequences of learning on clinical behavior and patient outcomes. Logging applications of new skills provides valuable data on patient care improvements. You are encouraged to update the log frequently, with reminders sent at 1 and 5 months after module completion.
Faculty
Jonathan Barratt, MD
Professor of Renal Medicine
University of Leicester, UK
Kirk Campbell, MD
C. Mahlon Kline Professor of Medicine
Chief, Renal-Electrolyte and Hypertension Division
University of Pennsylvania Perelman School of Medicine, PA, USA
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners and Nexus HE. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nurses Credentialing Center to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™ per episode. Physicians should claim only the credit commensurate with the extent of their participation.
Disclosures of Conflicts Of Interest
Jonathan Barratt
Received consultancy fees for providing speaker service to Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Argenx SE, Astellas Pharma, BioCryst Pharmaceuticals, Calliditas, Chinook Therapeutics, Dimerix, Galapagos NV, Novartis, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, and Visterra.
Received research grants from Argenx SE, Calliditas, Chinook Therapeutics, Galapagos NV, GlaxoSmithKline (GSK plc), Novartis, Omeros Corporation, Travere Therapeutics, and Visterra.
Kirk Campbell
Received consultancy, advisor, and speaker frees from AstraZeneca, Calliditas, Novartis, Otsuka Pharmaceutical, Sanofi, and Vera Therapeutics.
Computer System Hardware/Software Requirements:
To access and participate in this activity hosted on the Nexus HE Learning HUB, users will need a desktop or laptop computer running Windows (version 10 or later) or macOS (version 10.14 or later). Alternatively, mobile devices such as iOS devices (iOS 14 or later) or Android devices (Android 8.0 or later) can be used. A stable broadband internet connection with a minimum download speed of 5 Mbps is required for streaming audio content. Participants should use a web browser such as Google Chrome (latest version, recommended), Microsoft Edge (latest version), Safari (latest version), or Mozilla Firefox (latest version) to access the platform. For audio playback, built-in or external speakers or headphones are necessary.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indication(s). The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and further their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions, contact [email protected].